Advertisement

Ads Placeholder
Loading...

Dishman Carbogen Amcis Limited

DCAL.BOBSE
Healthcare
Biotechnology
147.40
1.50(1.03%)
Indian Market opens in 34h 47m

Dishman Carbogen Amcis Limited Fundamental Analysis

Dishman Carbogen Amcis Limited (DCAL.BO) shows weak financial fundamentals with a PE ratio of 19.40, profit margin of 4.25%, and ROE of 2.00%. The company generates $28.1B in annual revenue with moderate year-over-year growth of 3.66%.

Key Strengths

Cash Position27.41%
PEG Ratio-1.49

Areas of Concern

ROE2.00%
Operating Margin8.09%
We analyze DCAL.BO's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 30.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
30.3/100

We analyze DCAL.BO's fundamental strength across five key dimensions:

Efficiency Score

Weak

DCAL.BO struggles to generate sufficient returns from assets.

ROA > 10%
1.07%

Valuation Score

Excellent

DCAL.BO trades at attractive valuation levels.

PE < 25
19.40
PEG Ratio < 2
-1.49

Growth Score

Weak

DCAL.BO faces weak or negative growth trends.

Revenue Growth > 5%
3.66%
EPS Growth > 10%
1.02%

Financial Health Score

Excellent

DCAL.BO maintains a strong and stable balance sheet.

Debt/Equity < 1
0.40
Current Ratio > 1
1.10

Profitability Score

Weak

DCAL.BO struggles to sustain strong margins.

ROE > 15%
199.96%
Net Margin ≥ 15%
4.25%
Positive Free Cash Flow
No

Key Financial Metrics

Is DCAL.BO Expensive or Cheap?

P/E Ratio

DCAL.BO trades at 19.40 times earnings. This indicates a fair valuation.

19.40

PEG Ratio

When adjusting for growth, DCAL.BO's PEG of -1.49 indicates potential undervaluation.

-1.49

Price to Book

The market values Dishman Carbogen Amcis Limited at 0.36 times its book value. This may indicate undervaluation.

0.36

EV/EBITDA

Enterprise value stands at 0.63 times EBITDA. This is generally considered low.

0.63

How Well Does DCAL.BO Make Money?

Net Profit Margin

For every $100 in sales, Dishman Carbogen Amcis Limited keeps $4.25 as profit after all expenses.

4.25%

Operating Margin

Core operations generate 8.09 in profit for every $100 in revenue, before interest and taxes.

8.09%

ROE

Management delivers $2.00 in profit for every $100 of shareholder equity.

2.00%

ROA

Dishman Carbogen Amcis Limited generates $1.07 in profit for every $100 in assets, demonstrating efficient asset deployment.

1.07%

Following the Money - Real Cash Generation

Operating Cash Flow

Dishman Carbogen Amcis Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

Dishman Carbogen Amcis Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

DCAL.BO converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

19.40

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-1.49

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.36

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.83

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.40

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.10

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.02

vs 25 benchmark

ROA

Return on assets percentage

0.01

vs 25 benchmark

ROCE

Return on capital employed

0.03

vs 25 benchmark

How DCAL.BO Stacks Against Its Sector Peers

MetricDCAL.BO ValueSector AveragePerformance
P/E Ratio19.4028.45 Better (Cheaper)
ROE2.00%763.00% Weak
Net Margin4.25%-45265.00% (disorted) Weak
Debt/Equity0.400.34 Neutral
Current Ratio1.102795.60 Neutral
ROA1.07%-16588.00% (disorted) Weak

DCAL.BO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Dishman Carbogen Amcis Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

38.46%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-97.87%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-33.08%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ